Evidence map›Paper›PMID 41380106›Full record

ArticleJCO oncology practice2025

Clinician- and Facility-Level Factors Associated With Receipt of Nonguideline Chemotherapy Regimens in Women With Stage I-IIIA Breast Cancer.

Yashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, Jenna Bhimani, Victoria S Blinder, Rachael Burganowski, Isaac J Ergas, Grace B Gallagher, Jennifer J Griggs, Narre Heon and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Yashasvini SampathkumarDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0009-0007-2120-2620
Ziad ZakariaDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Kelli O'ConnellDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-4021-0788
Jenna BhimaniDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9962-7019
Victoria S BlinderDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-1448-8671
Rachael BurganowskiKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA.
Isaac J ErgasDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA.ORCID 0000-0002-3187-9754
Grace B GallagherDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0009-0004-9277-5002
Jennifer J GriggsDepartment of Medicine, Division of Hematology/Oncology and Department of Health Management and Policy, University of Michigan, Ann Arbor, MI.ORCID 0000-0002-1598-4562
Narre HeonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0009-0003-5239-0821
Tatjana KolevskaDepartment of Oncology, Kaiser Permanente Medical Center, Vallejo, CA.
Yuriy KotsurovskyyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Candyce H KroenkeDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA.ORCID 0000-0002-6128-3118
Cecile A LaurentDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA.ORCID 0000-0001-9332-6971
Raymond LiuDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA.ORCID 0000-0002-4667-9632
Kanichi G NakataKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA.ORCID 0000-0001-6730-6045
Sonia PersaudDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0009-0008-5666-7994
Janise M RohDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA.ORCID 0000-0002-8615-4320
Sara TabatabaiDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-5498-7176
Emily ValiceDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA.
Elisa V BanderaCancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.ORCID 0000-0002-8789-2755
Erin J Aiello BowlesKaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA.
Lawrence H KushiDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA.ORCID 0000-0001-9136-1175
Elizabeth D KantorDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9124-5323

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Risk-based Imaging Strategies to Improve Breast Cancer Surveillance OutcomesP01CA154292 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Diana L Miglioretti · 2011 to 2026
$52.9M
Infrastructure for Pathways, a Prospective Study of Breast Cancer SurvivorshipU01CA195565 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI AMBROSONE, CHRISTINE B., KUSHI, LAWRENCE H · 2016 to 2025
$18.8M
CRN4: Cancer Research Resources & Collaboration in Integrated Health Care SystemsU24CA171524 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI KUSHI, LAWRENCE H · 2012 to 2016
$16.0M
Obesity, chemotherapy dosing, and breast cancer outcomesR37CA222793 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KANTOR, ELIZABETH DAVID · 2018 to 2024
$4.0M
Oncology-focused Postdoctoral Training in Care Delivery and Symptom Science (OPTICS)T32CA275764 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JONINE L. BERNSTEIN, JUN J MAO · 2023 to 2026
$1.8M
Group Health Cancer Research Program Research Specialist AwardR50CA211115 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI BOWLES, ERIN JANELLE AIELLO · 2017 to 2021
$919k
NCI NIH HHS P01 CA154292NCI NIH HHS P30 CA008748NCI NIH HHS R37 CA222793NCI NIH HHS R50 CA211115NCI NIH HHS T32 CA275764NCI NIH HHS U01 CA195565NCI NIH HHS U24 CA171524
6 · The paper itself

Abstract

purposeWe examined clinician- and facility-level factors associated with selection of nonguideline chemotherapy at treatment initiation in women with stage I-IIIA breast cancer (BC).

methodsThe Optimal Breast Cancer Chemotherapy Dosing Study collected information on chemotherapy delivery in an integrated health care delivery system. This analysis included 9,758 women treated with chemotherapy for stage I-IIIA BC between 2006 and 2019 at Kaiser Permanente Northern California (KPNC). Prevalence ratios (PRs) and corresponding 95% CIs were estimated for the clinician and facility factors in relation to nonguideline regimen (NGR) use. Analyses were stratified by time (pre- and post-2015) to reflect the period before and after KPNC's transition to a subspecialized care model. Secondary outcomes focused on nonguideline drug combinations (NGDCs) and nonguideline administration schedules (NGASs).

resultsWomen treated by clinicians with substantially greater time since medical school (30+ years

conclusionClinician and facility characteristics significantly influenced the use of NGR in stage I-IIIA BC treatment. Notably, associations diminished over time, suggesting that health system changes in care delivery may enhance guideline adherence and reduce the impact of nonclinical factors on treatment decisions.

Identifiers

PMID41380106
PMCPMC12700344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.